Investigating how WNT5a and ROR2 affect prostate cancer progression
Official title: WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer
Funded at Beth Israel Deaconess Medical Center · NIH-11101311 · Data updated 2026-11-12
This study is looking at how certain proteins, WNT5a and ROR2, affect the growth of prostate cancer, especially when it stops responding to regular treatments, to find new ways to help improve care for patients with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $395,509 |
| NIH project number | 5R01CA272934-03 |
| Project ID | NIH-11101311 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with metastatic castration-resistant prostate cancer who have experienced treatment resistance.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone androgen deprivation therapy may not benefit from this research.
What this research studies
This research focuses on understanding the role of WNT5a and ROR2 in the progression of prostate cancer, particularly in cases where the cancer becomes resistant to standard treatments. The study aims to explore how these proteins influence the Hippo signaling pathway, which is involved in tumor growth and suppression. By examining the mechanisms of WNT signaling and its impact on cancer cell behavior, the research seeks to identify new therapeutic targets that could improve treatment outcomes for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the effectiveness of therapies for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promising results in targeting WNT signaling pathways in cancer, indicating potential for success in this novel approach.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Balk, Steven P. — Beth Israel Deaconess Medical Center
- Study coordinator: Balk, Steven P.
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.